

Approved by:



CERTIFICATE

2023

Teilgemeinschaftspraxis Molekularpathologie Südbayern
Giesinger Bahnhofplatz 2
81539 München
Germany

has successfully completed the proficiency test

PIK3CA Mutation Analysis Breast Cancer Tissue (MolPath)

(Trial Period 16.10.2023 - 27.10.2023)

Berlin, January 22, 2024

Prof. Dr. med. Dr. h.c. Manfred Dietel
Quality in Pathology - QuIP GmbH

Thomas Pilz, Managing Director
Quality in Pathology - QuIP GmbH

Lead panel institute of the proficiency test:
PD Dr. med. habil. R. Erber, Prof. Dr. med. A. Hartmann, University Hospital Erlangen, Germany

This certificate includes the separate individual evaluation of the test and the corresponding proficiency test report.

This proficiency test was organized by:
Qualitätssicherungs-Initiative Pathologie QuIP GmbH /
Reinhardtstr. 1 / 10117 Berlin / office@quip.eu / www.qualityinpathology.com

